Analysis Of Income And Expense [Abstract]

Egetis Therapeutics - Filing #701621

Concept	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue	—	—	—	38 243 SEK	—	—	—	40 662 SEK	—	—
Material income and expense [abstract]
Other operating income (expense)	—	—	—	598,000 SEK	—	—	—	243,000 SEK	—	—
Revenue and other operating income	—	—	—	38 543 SEK	—	—	—	40 662 SEK	—	—
Expenses by nature [abstract]
Classes of employee benefits expense [abstract]
Employee benefits expense	—	—	—	30 131 SEK	—	—	—	22 151 SEK	—	—
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss	—	—	—	2 455 SEK	—	—	—	395,000 SEK	—	—
Other expenses, by nature	—	—	—	14 513 SEK	—	—	—	10 001 SEK	—	—
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	– SEK	– SEK	– SEK	104 542 SEK	104 542 SEK	178 024 SEK	– SEK	178 024 SEK	– SEK	– SEK